Endothelial Dysfunction and Low-Grade Inflammation Are Associated With Greater Arterial Stiffness Over a 6-Year Period

Bas C. van Bussel, Fleur Schouten, Ronald M. Henry, Casper G. Schalkwijk, Michiel R. de Boer, Isabel Ferreira, Yvo M. Smulders, Jos W. Twisk, Coen D. Stehouwer

Abstract—Endothelial dysfunction and low-grade inflammation are associated with cardiovascular disease. Arterial stiffening plays an important role in cardiovascular disease and, thus, may be a mechanism through which endothelial dysfunction and/or low-grade inflammation lead to cardiovascular disease. We investigated the associations between, on the one hand, biomarkers of endothelial dysfunction (soluble endothelial selectin, thrombomodulin, and both vascular and intercellular adhesion molecules 1 and von Willebrand factor) and of low-grade inflammation (C-reactive protein, serum amyloid A, interleukin 6, interleukin 8, tumor necrosis factor-α and, soluble intercellular adhesion molecule 1) and, on the other hand, arterial stiffness over a 6-year period, in 293 healthy adults (155 women). Biomarkers were combined into mean z scores. Carotid, femoral, and brachial arterial stiffness and carotid-femoral pulse wave velocity were determined by ultrasonography. Measurements were obtained when individuals were 36 and 42 years of age. Associations were analyzed with generalized estimating equation and adjusted for sex, height, and mean arterial pressure. The endothelial dysfunction z score was inversely associated with femoral distensibility (β: −0.51 [95% CI: −0.95 to −0.06]) and compliance coefficients (β: −0.041 [95% CI: −0.076 to −0.006]) but not with carotid or brachial stiffness or carotid-femoral pulse wave velocity. The low-grade inflammation z score was inversely associated with femoral distensibility (β: −0.51 [95% CI: −0.95 to −0.07]) and compliance coefficients (β: −0.050 [95% CI: −0.084 to −0.016]) and with carotid distensibility coefficient (β: −0.910 [95% CI: −1.810 to −0.008]) but not with brachial stiffness or carotid-femoral pulse wave velocity. Biomarkers of endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness. This provides evidence that arterial stiffening may be a mechanism through which endothelial dysfunction and low-grade inflammation lead to cardiovascular disease. (Hypertension. 2011;58:00-00.) ● Online Data Supplement

Key Words: endothelial dysfunction ■ inflammation ■ arteriosclerosis ■ young adults ■ prospective study ■ epidemiology

From observational studies,1-3 it has become increasingly clear that biomarkers of endothelial dysfunction and low-grade inflammation are closely associated with (incident) cardiovascular disease. In part, these associations can be explained by the fact that endothelial dysfunction and low-grade inflammation play key roles in atherothrombosis.4 However, other mechanisms may also be important. In this respect, arterial stiffening may constitute one such mechanism. First, greater arterial stiffness has been shown to be independently associated with cardiovascular morbidity and mortality.7,8 Second, endothelial dysfunction and low-grade inflammation affect the composition of the subendothelial matrix, which is an important determinant of arterial stiffness.9

Indeed, the association between biomarkers of endothelial dysfunction and low-grade inflammation and greater arterial stiffness is receiving increasing attention.10,11 However, previous studies on this topic were cross-sectional,10-26 and most focused on either biomarkers of endothelial dysfunction24 or low-grade inflammation12,16-23,25,26 and were done in middle-aged or elderly populations.10,11,13-15,18-23,26 Importantly, endothelial dysfunction and low-grade inflammation are closely linked and difficult to separate conceptually,27 and any relationship with arterial stiffening may, therefore, be inter-
dependent. In addition, the process of arterial stiffening is known to start at an early age.28

In view of the above, we hypothesize that the development of biomarkers of endothelial dysfunction and low-grade inflammation is associated with arterial stiffening in early adulthood. Therefore, we have measured biomarkers of endothelial dysfunction, low-grade inflammation, and arterial stiffness twice in a population-based cohort, that is, for the first time at the age of 36 years and for the second time at the age of 42 years. We have investigated the 6-year longitudinal associations between biomarkers of endothelial dysfunction and low-grade inflammation, on the one hand, and stiffness estimates of the carotid, femoral, and brachial arteries and of the carotid-femoral segment, on the other, in apparently healthy adults of the Amsterdam Growth and Health Longitudinal Study.

Methods

Study Population

Data were derived from the Amsterdam Growth and Health Longitudinal Study, an observational, longitudinal study that started in 1976 with a group of 698 boys and girls (details described elsewhere).29 Briefly, its initial goal was to study the natural development of the growth, health, and lifestyle of adolescents and to investigate longitudinal relationships between biological and lifestyle variables. The mean age of the individuals at the start of the study was 13.1±0.8 years (mean±SD). Since then, extensive follow-up measurements have been done, and the cohort is still under investigation. At each follow-up measurement, anthropometric (body height, weight, and skinfolds), biological (blood pressure, serum lipoprotein levels, and physical fitness), lifestyle (nutritional habits, smoking behavior, and daily physical activity), and psychological variables were assessed.29

In addition, in blood samples of the individuals attending the 2000 and 2006 follow-up examinations (1 batch), 5 biomarkers of endothelial dysfunction and 6 biomarkers of low-grade inflammation were measured, and at both examinations arterial properties were assessed by ultrasonography. At the first ultrasound examination, 377 individuals participated, and complete data on stiffness estimates of the carotid, femoral, and brachial arteries were obtained in 373 individuals. From these, complete data on all 3 of the arteries were obtained in 293 individuals during the follow-up ultrasound examination, all of whom had full data on biomarkers of endothelial dysfunction and low-grade inflammation. The present study was, therefore, conducted with these 293 individuals.

The study was approved by the local ethics committee of the Vrije Universiteit University Medical Center, and all of the participants gave their written informed consent.

Assessment of Endothelial Dysfunction and Low-Grade Inflammation

Serum biomarkers of endothelial dysfunction (soluble intercellular adhesion molecule 1 [sICAM-1], soluble vascular cell adhesion molecule 1, soluble endothelial selectin, and soluble thrombomodulin), and of low-grade inflammation (C-reactive protein [CRP], serum amyloid A, interleukin 6, interleukin 8, tumor necrosis factor-α, and sICAM-1) were assessed by an electrochemiluminescence detection system using multiarray technology (SECTOR Imager 2400, Meso Scale Discovery), as described elsewhere30 (please see the online Data Supplement at http://hyper.ahajournals.org). In addition, a plasma biomarker of endothelial dysfunction (von Willebrand factor) was determined in citrated plasma by means of ELISA, as described elsewhere30 (please see the online Data Supplement).

Arterial Stiffness

We assessed local arterial stiffness of the carotid, femoral, and brachial arteries and central arterial stiffness (the carotid-femoral pulse wave velocity)31,32 (please see the online Data Supplement).

Other Measurements

Weight, height, body mass index, heart rate, and blood pressure were determined according to international standards, and smoking behavior was assessed by questionnaire as described previously.29 Total and high-density lipoprotein cholesterol, triglycerides, and glycohemoglobin were determined as described previously.29 Hypertension was defined as a systolic blood pressure >140 mm Hg, and/or a diastolic blood pressure >90 mm Hg, and/or treatment for hypertension.

Statistical Analyses

All of the analyses were performed with SPSS (version 15, SPSS). Variables with a skewed distribution (CRP, serum amyloid A, interleukin 6, and triglycerides) were transformed using a natural logarithm (ln). Overall z scores were calculated for endothelial dysfunction or low-grade inflammation (please see the online Data Supplement). We used generalized estimating equations to examine the associations between either the overall z score for endothelial dysfunction or the overall z score for low-grade inflammation and arterial stiffness over the 6-year study period. In these analyses an exchangeable correlation structure was used. Generalized estimating equation analysis is a method for longitudinal data analyses and takes into account the correlation of repeated measurements within individuals over time.33

First, we investigated the associations between the overall z scores for either endothelial dysfunction or low-grade inflammation on the one hand and arterial stiffness estimates on the other with adjustment for sex, height, and mean arterial pressure. Second, the analyses were repeated with mutual adjustments for the overall z scores for either low-grade inflammation or endothelial dysfunction. Third, to gain further insight into which of the individual elements of the stiffness formulas might have been primarily responsible for any relationships between endothelial dysfunction or low-grade inflammation and arterial stiffness estimates, the analyses were repeated with the individual elements of the stiffness formulas (diameter, distension, pulse pressure, and intima-media thickness) as dependent variables.

Data are presented as mean (±SD) or median (interquartile range) for skewed variables and regression coefficients (β) with their 95% CIs. A 2-sided P value <0.05 was considered statistically significant.

Results

Table 1 shows the general characteristics, the biomarker concentrations, and the stiffness estimates of the study population. Systolic blood pressure remained stable (116 mm Hg), diastolic blood pressure increased (+5.5 mm Hg), pulse pressure decreased (−5.6 mm Hg), and heart rate decreased (−8.9 bpm) during the 6-year follow-up. Biomarkers of low-grade inflammation remained fairly stable over 6-year follow-up, except for a decrease in tumor necrosis factor-α. Biomarkers of endothelial dysfunction remained stable or increased over 6-year follow-up, except for a decrease in soluble endothelial selectin. Pulse pressure and femoral and brachial artery stiffness decreased during 6-year follow-up. Nevertheless, carotid artery stiffness increased (for distensibility coefficient [DC]: −1.00*10^−3/kPa; for Young elastic modulus: +0.025 *10^3/kPa) during the 6-year follow-up.
### Table 1. Characteristics of the Study Population

<table>
<thead>
<tr>
<th>Variables</th>
<th>2000</th>
<th>2006</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>36.6±0.6</td>
<td>42.6±0.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Women, %</td>
<td>52.9</td>
<td>52.9</td>
<td>. . .</td>
</tr>
<tr>
<td>Smoker, %</td>
<td>64.21.9</td>
<td>45.15.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>116.3±11.7</td>
<td>116.2±14.4</td>
<td>0.858</td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
<td>64.9±7.2</td>
<td>70.4±8.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Pulse pressure, mm Hg</td>
<td>51.4±6.5</td>
<td>45.8±9.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Mean arterial pressure, mm Hg</td>
<td>82.1±8.7</td>
<td>85.1±9.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Prevalence of hypertension, %</td>
<td>5.1</td>
<td>9.6</td>
<td>0.015</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>70.5±11.4</td>
<td>61.6±9.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Body height, cm</td>
<td>177.0±9.2</td>
<td>177.4±9.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Body weight, kg</td>
<td>75.8±12.7</td>
<td>77.9±13.7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>24.1±3.2</td>
<td>24.7±3.6</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Total cholesterol, mmol/L</td>
<td>5.0±0.9</td>
<td>5.0±0.8</td>
<td>0.315</td>
</tr>
<tr>
<td>High density lipoprotein cholesterol, mmol/L</td>
<td>1.4±0.4</td>
<td>1.7±0.4</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Triglycerides, mmol/L</td>
<td>1.0 (0.8 to 1.5)</td>
<td>1.0 (0.7 to 1.4)</td>
<td>0.018</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>5.2±0.4</td>
<td>5.4±0.4</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

**Biomarkers**

- C-reactive protein, mg/L: 0.8 (0.3 to 2.0) vs 0.8 (0.3 to 1.8), 0.946
- Serum amyloid A, mg/L: 1.2 (0.7 to 2.2) vs 1.3 (0.7 to 2.3), 0.099
- Interleukin 6, ng/L: 2.3 (1.7 to 3.7) vs 2.4 (1.8 to 3.7), 0.664
- Interleukin 8, ng/L: 9.2±3.4 vs 9.5±4.1, 0.190
- Tumor necrosis factor-α, ng/L: 9.3±3.4 vs 9.0±3.3, 0.006
- Soluble intercellular adhesion molecule 1, μg/L: 203.3±52.4 vs 200.3±41.2, 0.142
- Soluble vascular cellular adhesion molecule 1, μg/L: 332.8±81.2 vs 333.9±69.2, 0.767
- Soluble endothelial selectin, μg/L: 10.5±4.7 vs 10.1±4.6, 0.016
- Soluble thrombomodulin, μg/L: 2.47±0.66 vs 2.53±0.62, 0.023
- von Willebrand factor, %: 102.5±40.0 vs 112.8±42.4, <0.001

**Carotid artery**

- Distensibility coefficient, 10⁻³/kPa: 26.7±6.1 vs 25.7±7.2, 0.014
- Compliance coefficient, mm²/kPa: 1.0±0.3 vs 1.0±0.3, 0.143
- Young elastic modulus, 10¹⁰Pa: 0.44±0.13 vs 0.47±0.16, 0.007
- Diameter, mm: 6.9±0.6 vs 7.1±0.7, <0.001
- Distension, mm: 0.6±0.1 vs 0.5±0.1, <0.001
- Pulse pressure, mm Hg: 51.3±7.1 vs 45.9±9.4, <0.001
- Intima-media thickness, mm: 0.62±0.10 vs 0.66±0.12, <0.001

**Femoral artery**

- Distensibility coefficient, 10⁻³/kPa: 7.1±3.7 vs 8.3±4.5, <0.001
- Compliance coefficient, mm²/kPa: 0.51±0.24 vs 0.63±0.33, <0.001
- Diameter, mm: 9.8±1.3 vs 10.0±1.5, <0.001
- Distension, mm: 0.22±0.10 vs 0.23±0.10, 0.149
- Pulse pressure, mm Hg: 51.4±7.2 vs 46.5±9.8, <0.001

**Brachial artery**

- Distensibility coefficient, 10⁻³/kPa: 14.6±9.2 vs 17.6±11.2, <0.001
- Compliance coefficient, mm²/kPa: 0.17±0.09 vs 0.21±0.11, <0.001
- Diameter, mm: 4.0±0.7 vs 4.0±0.7, 0.187
- Distension, mm: 0.18±0.09 vs 0.19±0.10, 0.205
- Pulse pressure, mm Hg: 51.7±7.2 vs 45.0±9.5, <0.001

**Central arterial stiffness**

- Pulse wave velocity, m/s: 7.7±1.6* vs 8.3±1.6†, <0.001

---

Data are reported as mean±SD, median (interquartile range), or percentage, as appropriate; P value, paired t test or McNemar test, as appropriate; n=293.

* n=241.
† n=292.
Endothelial Dysfunction, Low-Grade Inflammation, and Arterial Stiffness

The endothelial dysfunction overall z score was inversely associated with the femoral artery DC (β = −0.51 [95% CI: −0.95 to −0.06]; P = 0.025) and compliance coefficient (CC; β = −0.041 [95% CI: −0.076 to −0.006]; P = 0.020) after adjustment for sex, height, and mean arterial pressure, whereas it was not associated with carotid or brachial artery stiffness (Table 2, model 1). Additional adjustment for the low-grade inflammation overall z score decreased the regression coefficient (β) for the femoral artery DC by 32% and for the femoral artery CC by 46% (Table 2, model 2). In addition, the low-grade inflammation overall z score was not associated with carotid-femoral pulse wave velocity after adjustment for sex, height, and mean arterial pressure (β = −0.074 [95% CI: −0.37 to −0.24]; P = 0.526).

Endothelial Dysfunction, Low-Grade Inflammation, and Arterial Diameter, Distension, Pulse Pressure, and Intima-Media Thickness

The inverse associations between the endothelial dysfunction overall z score and the femoral artery DC and CC and the low-grade inflammation overall z score and the femoral artery DC and CC were primarily driven through inverse associations with femoral artery distension (for endothelial dysfunction: β = −0.013 [95% CI: −0.025 to −0.001]; P = 0.029; for low-grade inflammation: β = −0.015 [95% CI: −0.027 to −0.004]; P = 0.010; please see the online Data Supplement for Table S1). In contrast, the inverse association between the low-grade inflammation overall z score and the carotid artery DC was not primarily driven through any of the elements of the stiffness formulas (Table S1).

Additional Analyses

Additional adjustment for age (the age range by design being extremely narrow), smoking behavior, total and high-density lipoprotein cholesterol, and hypertension did not materially change the associations, whereas adjustment for weight did attenuate the regression coefficients with ≈50% (Table S2). None of the individuals had diabetes mellitus.
In the analyses for the individual elements of the low-grade inflammation z score, the results showed that ln serum amyloid A and lnCRP were the strongest determinants of the carotid artery DC (Figure A), whereas sICAM-1 and ln interleukin 6 were the strongest determinants of the femoral artery DC (Figure B) and sICAM-1 and lnCRP were the strongest determinants for the femoral artery CC (Figure C). For the endothelial dysfunction z score, sICAM-1 and soluble endothelial selectin were the strongest determinants for the femoral artery DC (Figure B) and CC (Figure C).

To investigate whether the longitudinal associations (by generalized estimating equation) were primarily determined by the between- or the within-subject associations over the 6-year study period, we calculated changes (ie, within-subject) in the endothelial dysfunction overall z score, the low-grade inflammation overall z score, and the arterial compliance coefficient (mm²/kPa).
Discussion

The present investigation is the first to prospectively evaluate, in apparently healthy adults, the relationship between the development of an extensive array of biomarkers of endothelial dysfunction and low-grade inflammation on the one hand and arterial stiffness on the other. The study had 3 main findings. First, biomarker scores for endothelial dysfunction and low-grade inflammation were associated with greater arterial stiffness over a 6-year period. The biomarker score for endothelial dysfunction was associated with greater femoral artery stiffness, whereas the biomarker score for low-grade inflammation was associated with both greater carotid and femoral artery stiffness. However, both the biomarker scores for endothelial dysfunction and low-grade inflammation were not associated with stiffness of the carotid-femoral segment. Endothelial dysfunction and/or low-grade inflammation may, thus, affect arterial stiffening in a way that depends on the arterial territory under study. Second, mutual adjustment for either the biomarker score for low-grade inflammation or endothelial dysfunction showed that the associations between either the biomarker score for endothelial dysfunction or low-grade inflammation with femoral artery stiffness were interdependent. Finally, the associations between each of the biomarker scores and greater femoral artery stiffness were primarily driven through decreased distension, whereas the association between low-grade inflammation and greater carotid stiffness was not primarily driven through any of the arterial parameters.

The endothelium has many functions and is itself heterogeneous. The concept of endothelial dysfunction, therefore, has many dimensions. von Willebrand factor, soluble vascular cell adhesion molecule 1, soluble endothelial selectin, soluble thrombomodulin, and sICAM-1 are all synthesized by endothelial cells, and higher concentrations of these biomarkers are associated with (incident) cardiovascular disease. Consequently, it is plausible to assume that higher circulating concentrations of these biomarkers reflect greater dysfunction.

A limitation of this study is that a measure of NO-mediated dilation, which represents an important function of the endothelium, was not available. Nevertheless, both biomarkers of the endothelium and NO-mediated dilation (eg, flow-mediated dilation) have been associated with (incident) cardiovascular disease.

Furthermore, endothelial dysfunction is closely linked with low-grade inflammation and, therefore, these concepts are difficult to separate. We, indeed, show that the associations with femoral artery stiffening are dependent on both endothelial dysfunction and low-grade inflammation, whereas this was not the case for carotid artery stiffening. This suggests that endothelial dysfunction and low-grade inflammation might affect arterial stiffening in concert or, independently, dependent on the arterial territory under study.

The present investigation was comprehensive and had advantages over previous ones, which investigated either biomarkers of endothelial dysfunction or low-grade inflammation, measured a less extensive array of biomarkers of endothelial dysfunction and low-grade inflammation, concerned middle-aged to elderly individuals, targeted 1 type of artery only, and were cross-sectional by design. On aggregate, previous studies have shown higher CRP levels to be associated with greater arterial stiffness of elastic, muscular, or both types of arteries, and higher interleukin 6 levels to be associated with greater elastic arterial stiffness. Taken together, these studies and the present results support the concept that low-grade inflammation may affect arterial stiffness. In particular, we show that this process is present even in young, apparently healthy adults.

With regard to biomarkers of endothelial dysfunction, previous studies have shown heterogeneous results for von Willebrand factor and sICAM-1, some reporting positive associations with elastic arterial stiffness, whereas others did not. We show that the overall endothelial dysfunction z score was significantly associated with femoral artery stiffness (Figure B and C), whereas none of the individual endothelial dysfunction biomarkers was, except for sICAM-1. This may be explained by the fact that, in these young, apparently healthy individuals, endothelial dysfunction may not be very far advanced and, therefore, only the sum of endothelial dysfunction biomarkers reveals its association with greater arterial stiffness.

Endothelial dysfunction may influence arterial stiffening by affecting vascular smooth muscle cell tone because of the reduced availability of NO and the increased activity of vasoconstrictor substances such as endothelin and by affecting the composition of the extracellular matrix. In addition, inflammation may induce both functional and structural changes in the arterial wall via the increased production of reactive oxygen species, which, in turn, triggers an inflammatory process leading to the proliferation of smooth muscle cells, the influx of leukocytes, and the production of proinflammatory substances and chemotaxin.
and matrix proteins), which, in turn, leads to a decrease in (femoral) distension. Taken together, the above suggests that endothelial dysfunction and low-grade inflammation may affect arterial stiffness of either muscular or elastic arteries differently. This might explain why endothelial dysfunction and low-grade inflammation were not associated with carotid-femoral pulse wave velocity, because the carotid-femoral segment includes both elastic and muscular arterial components. Alternatively, the adults investigated were young and did not have central arterial stiffening, which typically occurs after the age of 60 years.7

Additional adjustment for potential confounders did not materially change the results, whereas adjustment for body weight attenuated the associations between biomarkers of endothelial dysfunction or low-grade inflammation and arterial stiffness. However, it is questionable whether body weight should be seen as a true confounder in this relationship. It is biologically more plausible that body weight is part of the causal pathway, that is, body weight influences biomarkers of endothelial dysfunction and low-grade inflammation,40 and these influence arterial stiffening.9

Finally, the time frame in which endothelial dysfunction or low-grade inflammation have their possible impacts on arterial stiffness is unknown and might differ from the 6-year period of the present investigation. (This might explain why changes in biomarkers of endothelial dysfunction or low-grade inflammation did not parallel changes in arterial stiffness.) The question remains for what period a person should have endothelial dysfunction or low-grade inflammation before it affects the vasculature. In any case, our results may suggest that any inflammatory changes that have led to arterial stiffening have already occurred before the age of 36 years.

The present investigation had some limitations. First, intrinsic to an overall z score is the assumption that each biomarker in the z score carries similar weight. This might have caused us to underestimate the reported associations because of error attributed to a mathematical approach that might not optimally reflect pathophysiology. Second, the increase in diastolic blood pressure of 6 mm Hg and the practically unchanged levels of systolic blood pressure between the ages of 36 and 42 years in this study population led to a decrease in pulse pressure. Although this may seem “unexpected,” increases in pulse pressure with ageing are often observed after the fifth or sixth decades of life as a consequence of arterial stiffening.7 In addition, these changes were in line with previous life course trends in changes of the 2 blood pressure components in this cohort, showing steeper changes differentially along the arterial tree. These data may help us to understand the pathophysiology of early arterial stiffening and may provide potential targets for intervention.

**Perspectives**

Both scores of biomarkers for endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness in apparently healthy adults over a 6-year period. This suggests that arterial stiffness may be a mechanism through which endothelial dysfunction and low-grade inflammation lead to cardiovascular disease. In addition, the results showed that, early in the development of arterial stiffening, endothelial dysfunction and low-grade inflammation act differentially along the arterial tree. These data may help us to understand the pathophysiology of early arterial stiffening and may provide potential targets for intervention.

**Acknowledgments**

We thank Marjo van de Waarenburg (Department of Medicine, Maastricht University Medical Centre) for her excellent technical laboratory assistance.

**Sources of Funding**

This work was supported by the Top Institute Food and Nutrition (Wageningen, The Netherlands); Diet and Endothelial Function (project A1004; to B.C.v.B., R.M.H., C.G.S., and C.D.S.); and by a postdoctoral research grant (2006T050) from The Netherlands Heart Foundation (to I.F.). Throughout the years, the Amsterdam Growth and Health Longitudinal Study was supported by grants from the Foundation for Educational Research; the Dutch Prevention Fund; The Netherlands Heart Foundation; the Dutch Ministry of Public Health, Well Being and Sport; the Dairy Foundation on Nutrition and Health; The Netherlands Olympic Committee/Netherlands Sports Federation; Heineken BV; and the Scientific Board on Smoking and Health.

**Disclosures**

None.

**References**


Endothelial Dysfunction and Low-Grade Inflammation Are Associated With Greater Arterial Stiffness Over a 6-Year Period
Bas C. van Bussel, Fleur Schouten, Ronald M. Henry, Casper G. Schalkwijk, Michiel R. de Boer, Isabel Ferreira, Yvo M. Smulders, Jos W. Twisk and Coen D. Stehouwer

Hypertension, published online August 22, 2011:
Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2011 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/early/2011/08/22/HYPERTENSIONAHA.111.174557

Data Supplement (unedited) at:
http://hyper.ahajournals.org/content/suppl/2011/08/19/HYPERTENSIONAHA.111.174557.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/
ENDOTHELIAL DYSFUNCTION AND LOW-GRADE INFLAMMATION ARE ASSOCIATED WITH GREATER ARTERIAL STIFFNESS OVER A 6-YEAR PERIOD

Bas C. van Bussel*, Fleur Schouten*, Ronald M. Henry, Casper G. Schalkwijk, Michiel R. de Boer, Isabel Ferreira, Yvo M. Smulders, Jos W. Twisk, Coen D. Stehouwer

* both authors contributed equally

From the Departments of Medicine (B.C.v.B., R.M.H., C.G.S., I.F., C.D.S.) and Clinical Epidemiology and Medical Technology Assessment (I.F.), the Cardiovascular Research Institute Maastricht (CARIM) (R.M.H., C.G.S., I.F., C.D.S.), the School for Public Health and Primary Care (CAPHRI) (I.F.) and the School for Nutrition, Toxicology and Metabolism (NUTRIM) (B.C.v.B., C.D.S.), Maastricht University Medical Centre, Maastricht; Top Institute Food and Nutrition (TIFN), Wageningen (B.C.v.B., R.M.H., C.G.S., C.D.S.); Department of Health Sciences and the EMGO Institute for Health and Care Research, Faculty of Earth and Life Sciences, VU University Amsterdam (F.S., M.R.d.B., J.W.T.); Institute for Cardiovascular Research ICaR-VU, VU University Medical Center, Amsterdam (F.S., Y.M.S.); and Department of Medicine, VUMc, Amsterdam (Y.M.S., J.W.T.); all in The Netherlands.

Short title: Endothelium, inflammation, arterial stiffness

Corresponding Author:
Professor C.D.A. Stehouwer PhD MD
Maastricht University Medical Centre, Dept. of Medicine
Prof. Debyelaan 25, 6229 HX MAASTRICHT, The Netherlands
Telephone: +31 (0)43 3876543; Fax: +31 (0)43 3875006
E-mail: cda.stehouwer@mumc.nl
ONLINE SUPPLEMENT

Assessment of endothelial dysfunction and low-grade inflammation

The electro-chemiluminescence detection system uses multi-array plates fitted with multi-electrodes per well with each electrode being coated with a different catching antibody. The assay procedure then follows that of a classic sandwich enzyme linked immunosorbent assay (ELISA) with any of the analytes of interest captured on the relevant electrode. These captured analytes were then in turn detected by a secondary analyte-specific ruthenium-conjugated antibody, which is capable of emitting light after electrochemical stimulation. A particular advantage of this system is the ability to measure different biomarkers of endothelial dysfunction and (or) low-grade inflammation simultaneously in relatively small (25 or 50 µl) serum samples. In our laboratory intra- and inter-assay coefficients of variation were for sVCAM-1, 3.8 and 6.9%; for sE-selectin, 4.1 and 8.6%; for sTM, 2.5 and 8.1%; for sICAM-1, 2.6 and 6.0%; for CRP, 2.3 and 4.3%; for SAA, 4.5 and 9.0%; for IL-6, 6.3 and 17.5%; for IL-8, 6.9 and 7.3%; and for TNFα, 5.9 and 12.6%, respectively. We also measured IL-1β, but levels were below the detection limit in 107 participants (resulting in intra- and inter-assay variation coefficients of 20.0 and 32.2%, respectively), and therefore we excluded IL-1β from the present investigation.

For the von Willebrand factor (vWF) ELISA, vWF rabbit anti-body was used as a catching antibody and a peroxidase-conjugate rabbit antibody as detecting antibody. Levels were expressed as a percentage of vWF detected in pooled citrated plasma of healthy volunteers. Intra- and inter-assay coefficients of variation for vWF were 3.8 and 7.4%, respectively.
Assessment of arterial stiffness
Arterial stiffness of the carotid, femoral and brachial artery was determined according to international guidelines and the exact procedures for the AGAHLS cohort, as executed in the 2000 follow-up, have been described elsewhere. Briefly, arterial diameter (D), intima-media thickness (IMT) and distension (∆D) were quantified by ultrasonography and local pulse pressure (PP) was determined according to the Van Bortel calibration method of distension waveforms. Arterial stiffness was then calculated according to the following formulas:

- Distensibility Coefficient (DC)
  \[ DC = \frac{2\Delta D \cdot D + \Delta D^2}{PP \cdot D^2} \quad (10^{-3} \cdot \text{kPa}^{-1}) \]

- Compliance Coefficient (CC)
  \[ CC = \pi \cdot \frac{2D \cdot \Delta D + \Delta D^2}{4PP} \quad (\text{mm}^2 \cdot \text{kPa}^{-1}) \]

- Young’s elastic modulus (YEM)
  \[ E_{\text{inc}} = \frac{D}{\text{IMT} \cdot DC} \quad (10^3 \cdot \text{kPa}) \]

DC represents local arterial stiffness; CC represents the arterial buffering capacity; and YEM represents the intrinsic stiffness of the arterial wall.

In addition, central arterial stiffness [the carotid-femoral pulse wave velocity (cfPWV, in m/s)] was measured by dividing the length between the carotid and the femoral arterial sites by the carotid-to-femoral transit time. The carotid-to-femoral transit time was calculated by subtracting the travel time of the pressure wave from the heart (as triggered) to the femoral artery by that from the heart to the carotid artery. For technical reasons, cfPWV was obtained only in 241 individuals in 2000 and in 292 individuals in 2006.

Calculation of overall Z-scores for endothelial dysfunction and low-grade inflammation
For reasons of statistical efficiency and to reduce the influences of the biological variability of each measure, overall Z-scores were determined for both endothelial dysfunction and low-grade inflammation in 2000 and 2006, according to predefined clusters of conceptually related biomarkers. These overall Z-scores were calculated as follows: first, for each individual biomarker a Z-score was calculated according to the formula: (individual value – population mean) / population standard deviation. The resulting individual Z-scores were then averaged into the overall Z-score for either endothelial dysfunction or low-grade inflammation. The endothelial dysfunction overall Z-score consisted of the biomarkers sICAM-1, sVCAM-1, sE-selectin, sTM and vWF. The low-grade inflammation overall Z-score consisted of the biomarkers CRP, SAA, IL-6, IL-8, TNF-α and sICAM-1. sICAM-1 levels were included in both overall Z-scores as it is expressed by both monocytes and the endothelium and is strongly affected by inflammatory stimuli.
References


S1. Longitudinal associations between, on the one hand, endothelial dysfunction and low-grade inflammation Z-scores during 6-year follow-up and, on the other hand, elements of the arterial stiffness indices during 6-year follow-up (n=293)

<table>
<thead>
<tr>
<th>Endothelial dysfunction</th>
<th>Carotid artery</th>
<th></th>
<th></th>
<th>Femoral artery</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>β</td>
<td>95%CI</td>
<td>p-value</td>
<td>β</td>
<td>95%CI</td>
</tr>
<tr>
<td><strong>Diameter</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1: + sex, height, MAP</td>
<td>-0.008</td>
<td>-0.09;0.08</td>
<td>0.862</td>
<td>0.02</td>
<td>-0.12;0.15</td>
</tr>
<tr>
<td><strong>Distension</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1: + sex, height, MAP</td>
<td>0.007</td>
<td>-0.010;0.023</td>
<td>0.434</td>
<td>-0.013</td>
<td>-0.025;-0.001</td>
</tr>
<tr>
<td><strong>Pulse pressure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1: + sex, height, MAP</td>
<td>0.79</td>
<td>-0.53;2.13</td>
<td>0.240</td>
<td>0.53</td>
<td>-0.70;1.75</td>
</tr>
<tr>
<td><strong>Intima-media thickness</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1: + sex, height, MAP</td>
<td>0.006</td>
<td>-0.009;0.022</td>
<td>0.430</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Low-grade inflammation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diameter</strong></td>
</tr>
<tr>
<td>1: + sex, height, MAP</td>
</tr>
<tr>
<td><strong>Distension</strong></td>
</tr>
<tr>
<td>1: + sex, height, MAP</td>
</tr>
<tr>
<td><strong>Pulse pressure</strong></td>
</tr>
<tr>
<td>1: + sex, height, MAP</td>
</tr>
<tr>
<td><strong>Intima-media thickness</strong></td>
</tr>
<tr>
<td>1: + sex, height, MAP</td>
</tr>
</tbody>
</table>

βs, longitudinal regression coefficients that express the relationships between the longitudinal development of endothelial dysfunction and low-grade inflammation, on the one hand, and the longitudinal development of the elements of the arterial stiffness formulas on the other; 95%CI, indicate 95% confidence intervals and p-value; MAP = mean arterial pressure.
van Bussel & Schouten et al, Hypertension

S2. GEE Longitudinal associations between, on the one hand, endothelial dysfunction and low-grade inflammation z-scores during 6-year follow-up and, on the other hand, arterial stiffness indices during 6-year follow-up (N=293)

<table>
<thead>
<tr>
<th>Endothelial dysfunction</th>
<th>Carotid artery</th>
<th>β</th>
<th>95%CI</th>
<th>P-value</th>
<th>Brachial artery</th>
<th>β</th>
<th>95%CI</th>
<th>P-value</th>
<th>Femoral artery</th>
<th>β</th>
<th>95%CI</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Distensibility coefficient</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1: + sex, height, MAP</td>
<td>-0.19</td>
<td>-1.02;0.64</td>
<td>0.656</td>
<td></td>
<td>-0.94</td>
<td>-2.26;0.39</td>
<td>0.165</td>
<td></td>
<td>-0.51</td>
<td>-0.95;-0.06</td>
<td>0.025</td>
<td></td>
</tr>
<tr>
<td>2: 1 + smoking, total &amp; HDL cholesterol, age, hypertension*</td>
<td>-0.03</td>
<td>-0.81;0.756</td>
<td>0.947</td>
<td></td>
<td>-1.00</td>
<td>-2.29;0.30</td>
<td>0.131</td>
<td></td>
<td>-0.42</td>
<td>-0.87;0.02</td>
<td>0.060</td>
<td></td>
</tr>
<tr>
<td>3: 2 + weight</td>
<td>0.16</td>
<td>-0.62;0.94</td>
<td>0.681</td>
<td></td>
<td>-1.15</td>
<td>-2.45;0.14</td>
<td>0.081</td>
<td></td>
<td>-0.27</td>
<td>-0.72;0.19</td>
<td>0.249</td>
<td></td>
</tr>
<tr>
<td>4: 2 + eGFR in 2006 only†</td>
<td>-0.004</td>
<td>-0.88;0.77</td>
<td>0.992</td>
<td></td>
<td>-1.01</td>
<td>-2.30;0.29</td>
<td>0.128</td>
<td></td>
<td>-0.42</td>
<td>-0.86;0.02</td>
<td>0.063</td>
<td></td>
</tr>
<tr>
<td>Compliance coefficient</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1: + sex, height, MAP</td>
<td>-0.012</td>
<td>-0.049;0.026</td>
<td>0.539</td>
<td></td>
<td>-0.009</td>
<td>-0.023;0.004</td>
<td>0.163</td>
<td></td>
<td>-0.041</td>
<td>-0.076;-0.006</td>
<td>0.020</td>
<td></td>
</tr>
<tr>
<td>2: 1 + smoking, total &amp; HDL cholesterol, age, hypertension*</td>
<td>-0.008</td>
<td>-0.044;0.029</td>
<td>0.687</td>
<td></td>
<td>-0.011</td>
<td>-0.024;0.003</td>
<td>0.117</td>
<td></td>
<td>-0.036</td>
<td>-0.071;0.000</td>
<td>0.048</td>
<td></td>
</tr>
<tr>
<td>3: 2 + weight</td>
<td>-0.008</td>
<td>-0.044;0.029</td>
<td>0.683</td>
<td></td>
<td>-0.013</td>
<td>-0.026;0.000</td>
<td>0.050</td>
<td></td>
<td>-0.027</td>
<td>-0.064;0.010</td>
<td>0.155</td>
<td></td>
</tr>
<tr>
<td>4: 2 + eGFR in 2006 only†</td>
<td>-0.008</td>
<td>-0.045;0.029</td>
<td>0.683</td>
<td></td>
<td>-0.011</td>
<td>-0.024;0.002</td>
<td>0.111</td>
<td></td>
<td>-0.037</td>
<td>-0.071;-0.002</td>
<td>0.038</td>
<td></td>
</tr>
<tr>
<td>Young ’s elastic modulus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1: + sex, height, MAP</td>
<td>-0.001</td>
<td>-0.020;0.018</td>
<td>0.919</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2: 1 + smoking, total &amp; HDL cholesterol, age, hypertension*</td>
<td>-0.005</td>
<td>-0.024;0.014</td>
<td>0.587</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3: 2 + weight</td>
<td>-0.009</td>
<td>-0.028;0.009</td>
<td>0.315</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4: 2 + eGFR in 2006 only†</td>
<td>-0.005</td>
<td>-0.024;0.013</td>
<td>0.572</td>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Low-grade inflammation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distensibility coefficient</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1: + sex, height, MAP</td>
<td>-0.91</td>
<td>-1.81;-0.01</td>
<td>0.048</td>
<td></td>
<td>0.19</td>
<td>-1.11;1.49</td>
<td>0.777</td>
<td></td>
<td>-0.51</td>
<td>-0.95;-0.07</td>
<td>0.024</td>
<td></td>
</tr>
<tr>
<td>2: 1 + smoking, total &amp; HDL cholesterol, age, hypertension*</td>
<td>-0.65</td>
<td>-1.54;0.24</td>
<td>0.153</td>
<td></td>
<td>0.30</td>
<td>-0.97;1.57</td>
<td>0.644</td>
<td></td>
<td>-0.30</td>
<td>-0.74;0.14</td>
<td>0.185</td>
<td></td>
</tr>
</tbody>
</table>
### Compliance coefficient

<table>
<thead>
<tr>
<th>Model</th>
<th>Factors</th>
<th>β</th>
<th>95%CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1: + sex, height, MAP</td>
<td>-0.022</td>
<td>-0.061:0.18</td>
<td>0.288</td>
<td>0.005</td>
</tr>
<tr>
<td>2: 1 + smoking, total &amp; HDL cholesterol, age, hypertension*</td>
<td>-0.016</td>
<td>-0.054:0.022</td>
<td>0.414</td>
<td>0.006</td>
</tr>
<tr>
<td>3: 2 + weight</td>
<td>-0.017</td>
<td>-0.053:0.020</td>
<td>0.374</td>
<td>0.003</td>
</tr>
<tr>
<td>4: 2 + eGFR in 2006 only†</td>
<td>-0.015</td>
<td>-0.053:0.024</td>
<td>0.448</td>
<td>0.006</td>
</tr>
</tbody>
</table>

### Young’s elastic modulus

<table>
<thead>
<tr>
<th>Model</th>
<th>Factors</th>
<th>β</th>
<th>95%CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1: + sex, height, MAP</td>
<td>0.006</td>
<td>-0.013:0.024</td>
<td>0.556</td>
<td>-</td>
</tr>
<tr>
<td>2: 1 + smoking, total &amp; HDL cholesterol, age, hypertension*</td>
<td>0.001</td>
<td>-0.018:0.020</td>
<td>0.925</td>
<td>-</td>
</tr>
<tr>
<td>3: 2 + weight</td>
<td>-0.006</td>
<td>-0.025:0.013</td>
<td>0.531</td>
<td>-</td>
</tr>
<tr>
<td>4: 2 + eGFR in 2006 only†</td>
<td>0.002</td>
<td>-0.016:0.021</td>
<td>0.808</td>
<td>-</td>
</tr>
</tbody>
</table>

βs, longitudinal regression coefficients that express the relationships between the longitudinal development of endothelial dysfunction and low-grade inflammation on the one hand and the longitudinal development of arterial stiffness on the other; 95%CI, indicate 95% confidence intervals; MAP, mean arterial pressure; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease short formula as follows: $175 \cdot (\text{serum creatinine})^{-1.154} \cdot (\text{age})^{-0.203} \cdot 1.212 \cdot (\text{if black}) \cdot 0.742 \cdot (\text{if female})$; * hypertension defined as systolic blood pressure >140, diastolic blood pressure <90 mmHg and/or treatment for hypertension; † only determined in 2006.